Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Arthritis Rheumatol. 2016 May;68(5):1262–1271. doi: 10.1002/art.39558

Figure 1. Anti-IFI16 antibody levels are significantly higher in scleroderma patients compared to healthy controls, and associate with a lower DLCO.

Figure 1

(A) Anti-IFI16 antibody levels in patients with scleroderma and healthy controls were assayed by ELISA. Calibrated optical density levels are significantly higher (p=0.01) in patients with scleroderma than healthy controls (n=94 scleroderma, n=47 controls). (B) Amongst scleroderma patients, DLCO is significantly lower (p<0.01) in anti-IFI16 antibody positive patients compared to those without this specificity (antibody positive, n = 17; antibody negative, n = 77).